Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 205625

Expand all

ARNUITY ELLIPTA (FLUTICASONE FUROATE)
0.05MG/INH Marketing Status: Prescription

Active Ingredient: FLUTICASONE FUROATE
Proprietary Name: ARNUITY ELLIPTA
Dosage Form; Route of Administration: POWDER; INHALATION
Strength: 0.05MG/INH
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N205625
Product Number: 003
Approval Date: May 17, 2018
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
Marketing Status:  Prescription
Patent and Exclusivity Information

ARNUITY ELLIPTA (FLUTICASONE FUROATE)
0.1MG/INH Marketing Status: Prescription

Active Ingredient: FLUTICASONE FUROATE
Proprietary Name: ARNUITY ELLIPTA
Dosage Form; Route of Administration: POWDER; INHALATION
Strength: 0.1MG/INH
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N205625
Product Number: 001
Approval Date: Aug 20, 2014
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
Marketing Status:  Prescription
Patent and Exclusivity Information

ARNUITY ELLIPTA (FLUTICASONE FUROATE)
0.2MG/INH Marketing Status: Prescription

Active Ingredient: FLUTICASONE FUROATE
Proprietary Name: ARNUITY ELLIPTA
Dosage Form; Route of Administration: POWDER; INHALATION
Strength: 0.2MG/INH
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N205625
Product Number: 002
Approval Date: Aug 20, 2014
Applicant Holder Full Name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English